Stay updated with breaking news from Provide Runway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EstablishedExclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared
Updates from OTL-201 Clinical Proof-of-Concept Study in MPS-IIIA and OTL-204 Preclinical Study for GRN-FTD at ESGCT Showcase Potential for HSC Gene Therapy...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates - read this article along with other careers information, tips and advice on BioSpace
TM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany Update on OTL-200 U.S. BLA Filing Strategy for MLD on Track for Mid-2021 Following Type B RMAT Meeting with FDA Recent Publications, Including ADA-SCID Dataset in NEJM and Multiple Oral Presentations at ASGCT, Highlight Broad and Innovative Potential of HSC Gene Therapy Cash and Investments of Approximately $300M Provide Runway into First Half 2023 Following $150M Financing in February 2021 BOSTON and LONDON, May 13, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy lead...